J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
The Journal of Clinical Pharmacology and New Drugs, 1970; 10:207-211
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Smedt, R.
Right arrow Articles by Brugmans, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Smedt, R.
Right arrow Articles by Brugmans, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Dexbenzetimide in Neuroleptic-Induced Parkinsonism. A Double-Blind Crossover Study With a 16-Week Follow-Up

Raoul de Smedt M.D.1, Etienne Rodrigus M.D.1, Robert Debandt M.D.1, and Jo Brugmans M.D.1

1 Mental Hospital of the Brothers of Charity, Mortsel, Antwerp, Belgium; Department of Clinical Pharmacology of Janssen Pharmaceutica, Beerse, Belgium.

A double-blind crossover trial with a 16-week follow-up was performed to objectively assess the therapeutic efficacy, dosage, and safety of dexbenzetimide (R 16470), a new antiparkinsonian agent. Sixteen male psychiatric patients with neuroleptie-induced extrapyramidal symptoms were included in the study. The optimum dose of dexbenzetimide was a single daily oral administration of 0.75 to 1.5 mg. Dexbenzetimide was significantly superior to placebo in reducing the incidence of neuroleptic-induced parkinsonian symptoms.

Blood examinations showed no evidence of toxic effects.

Dexbenzetimide compared favorably with the known anitparkinsonian agents by its 24-hour duration of action and by its beneficial effects on the mood and alertness.

Note:

We should like to thank Miss V. Schuermans for her help in the preparation of the manuscript.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1970 by the American College of Clinical Pharmacology